Differentiation of human embryonic stem cells
A technology of pluripotent stem cells and cells, applied in embryonic cells, artificial cell constructs, pancreatic cells, etc., can solve problems such as not completely simulating the developmental program of higher mammals
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 1
[0144] Human pluripotent stem cells express markers characteristic of the pancreatic endoderm lineage (Table 1 up to PDX1, NKX6.1, but not CDX2 and NGN3) differentiation
[0145] This example demonstrates that activin A can be used in combination with noggin and retinoic acid to promote the upregulation of NKX6.1 expression. Briefly, cells of the human embryonic stem cell line H1 were incubated in MATRIGEL TM (1:30 dilution) coated plate and supplemented with 2% BSA, 100ng / ml activin A, 20ng / ml WNT-3a, 8ng / ml bFGF cultured on the RPMI medium for one day, and then supplemented with 2%BSA , 100ng / ml activin A, 8ng / ml bFGF in RPMI medium for two days (phase 1), then
[0146]a. Treated with DMEM / F12+2%BSA+50ng / ml FGF7+0.25μM cyclopamine-KAAD for three days (stage 2), then
[0147] b. Use DMEM-high glucose+1% B27+50ng / ml FGF7+0.25μM cyclopamine-KAAD+2μM retinoic acid (RA)+100ng / ml Noggin+20ng / ml Activin A or 50ng / ml Activin A treatment for four days (phase 3).
[0148] As a...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com